CINCINNATI, June 3 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research
"Kendle's ability to forge strong and collaborative relationships with investigative sites across the globe is key to our ability to deliver studies more efficiently and cost effectively for our customers, which is increasingly important in today's environment," said Stephen Cutler, PhD, Senior Vice President and Chief Operating Officer. "Our continued recognition as a top-rated CRO and the fact that we are the only CRO to have been ranked consistently among the top three providers since 2007 is a further testament to our ability to build long-lasting and successful site relationships in support of our customers' needs."
In the 2010 European Investigative Site Survey, 76.1 percent of sites rated Kendle "Good" or "Excellent" for overall relationship quality. In addition to excelling in the study initiation category Kendle also scored highly on the ongoing study conduct and grant payment performance attributes. In an article detailing the survey results in the June 2010 issue of The CenterWatch Monthly, CenterWatch notes "Kendle has stayed true to their word of continuous improvement from previous years— actively listening to the needs of investigative sites, implementing change when needed—and generally adopting a proactive strategy to strengthen their relationships with sites."
CenterWatch conducted the survey of investigative sites across Europe between January and March 2010. The biennial survey, which has been conducted since 1997 in both North America and Europe, was developed with input from clinical research professionals at sponsor companies, CROs and investigative sites. A total of 924 investigative sites completed the survey, which evaluated the performance of CROs across 29 specific relationship attributes relating to general project management, personnel and work-style and project-specific areas. In addition, sites also provided feedback on the importance of these attributes when conducting their clinical trials.
Kendle's rating as a top CRO in the 2010 European Investigative Site Survey follows its strong performance in the annual CenterWatch investigative site surveys during each of the past four years. In the 2009 CenterWatch survey of U.S. investigative sites Kendle ranked second with 72 percent of sites surveyed rating the Company as "Good" or "Excellent." Kendle also ranked second in the 2008 CenterWatch Survey of European Investigative Sites and ranked first overall in the 2007 CenterWatch Survey of U.S. Investigative Sites.
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.
SOURCE Kendle International Inc.
Subscribe to our Free Newsletters!
Statins are a group of drugs which help to lower the blood cholesterol levels.
Niemann-Pick disease is a group of inherited metabolic disorders in which cholesterol and lipids ...
Raspberries are packed with important nutrients, vitamins and minerals. They help boost immunity, ...View All